Skip to main content

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program

Written by Customer Service on . Posted in Public Companies.

NANTES, France, July 16, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This funding was awarded as part of the Metropolitan Fund to Support Health Innovations Linked to the COVID-19 Health Crisis, a €1 million fund created by Nantes Metropole for health innovations to address the COVID-19 health crisis.
“We thank Nantes Metropole for supporting us with a grant that will allow us to accelerate the development of a vaccine candidate against COVID-19. Our teams are diligently working to finalize the preclinical phase of this program based on a T lymphocyte response that can last over time to eliminate infected cells and avoid developing serious forms. We expect the first preclinical results confirming vaccine protection during this summer. Based on these results, we could launch the clinical phase at the end of the year, provided we have the funding required for this clinical study,” commented Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics.OSE Immunotherapeutics is committed in its effort to fight COVID-19 and is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope- peptide approach (epitopes modified to induce strong and sustained CD8 immune responses).To conduct this program, OSE Immunotherapeutics is leveraging its expertise in the selection and optimization of disease-relevant peptides and using its established Memopi® neo-epitope optimization technology to increase the memory immune response of T lymphocytes against specific antigens.Using a bioinformatics approach and algorithms for predicting immunogenicity in the virus genome, OSE Immunotherapeutics’ R&D team has screened a large number of peptides derived from different proteins of SARS-CoV-2, SARS-CoV (the virus responsible for SARS disease) and MERS-CoV (coronavirus of the Middle East respiratory syndrome) and has selected the immuno-dominant epitopes from 8 major proteins of coronaviruses.ABOUT THE METROPOLITAN FUND TO SUPPORT HEALTH INNOVATIONS LINKED TO THE COVID-19 HEALTH CRISIS WITH € 1M
This fund was created during the health crisis to support research and innovation projects including treatments, tests, protective equipment or any other health-related project as defined by the World Health Organization, namely “a state of complete physical, mental and social well-being,” which includes innovation in a number of sectors, including health & digital, health & food and health & materials. It is aimed at generating tools, services or means to limit the spread of the virus; to support the deconfinement of the population or acting in a preventive manner by aiming to limit the contamination risks (transport, food, etc.).ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical and preclinical portfolio has a diversified risk profile: Tedopi® (innovative combination of neoepitopes) : the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure; due to COVID-19, voluntary definitive stop of new patient accrual in the Step-2 initially planned in the trial.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination with checkpoint inhibitor Opdivo®.BI 765063 (OSE-172, anti-SIRPα monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in 2020.BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity. Additional innovative research programs.CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. First preclinical results expected Q3 2020, possible clinical trial start by year end.
Due to the COVID-19 crisis, accrual of new patients in the clinical trial TEDOPaM is temporarily suspended and initiation timelines for both Phase 2 trials of OSE-127 could be impacted during the coming months.For more information: https://ose-immuno.com/en/
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.